抗血管内皮生长因子药物治疗玻璃体切割术后新生血管性年龄相关性黄斑变性的疗效。
Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes.
机构信息
Department of Ophthalmology, Seoul National University College of Medicine, Seoul, South Korea.
Seoul National University Bundang Hospital, Seongnam, South Korea.
出版信息
PLoS One. 2021 Jun 10;16(6):e0252006. doi: 10.1371/journal.pone.0252006. eCollection 2021.
PURPOSE
To evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for treatment of neovascular age-related macular degeneration (nAMD) in vitrectomized eyes.
METHODS
The medical records were reviewed of nAMD patients treated with anti-VEGF agents who previously underwent pars plana vitrectomy (PPV). PPV was performed with complete posterior vitreous detachment induction.
RESULTS
A total of 44 eyes from 44 patients were included. The mean central foveal thickness (CFT) was 478.50 ± 156.93 μm at baseline, 414.25 ± 143.55 μm (86.6% of baseline) at 1 month after first injection (P < 0.001), and 386.75 ± 141.45 μm (80.8% of baseline) after monthly multiple injections (2.30 ± 1.07; range, 1-5) (P < 0.001). The mean logarithm of the minimum angle of resolution best-corrected visual acuity visual acuity (BCVA) was 0.85 ± 0.57 at baseline, 0.86 ± 0.63 after the first injection, and 0.84 ± 0.64 after monthly multiple injections. BCVA improved in 39.5% at 1 month after first injection and 45.2% at 1 month after monthly multiple injections. In the subgroup analysis, CFT of eyes with the posterior capsule decreased significantly to 85.8% and 79.8% of baseline values at 1 month after the first injection and after monthly multiple injections, respectively. CFT of eyes without the posterior capsule decreased to 91.6% and 87.4% of baseline values at 1 month after the first injection and after monthly multiple injections, respectively, without statistical significance.
CONCLUSION
Monthly injections of Intravitreal anti-VEGF agents induced favorable anatomical improvement and vision maintenance in vitrectomized eyes with nAMD.
目的
评估玻璃体内抗血管内皮生长因子（anti-VEGF）药物治疗玻璃体切割术后新生血管性年龄相关性黄斑变性（nAMD）的疗效。
方法
回顾性分析了接受抗 VEGF 药物治疗的 nAMD 患者的病历，这些患者之前曾接受过玻璃体切除术（PPV）。PPV 采用完全玻璃体后脱离诱导法进行。
结果
共纳入 44 例 44 只眼。基线时平均中央视网膜厚度（CFT）为 478.50 ± 156.93μm，首次注射后 1 个月为 414.25 ± 143.55μm（基线的 86.6%）（P < 0.001），每月多次注射后为 386.75 ± 141.45μm（基线的 80.8%）（2.30 ± 1.07；范围，1-5）（P < 0.001）。最佳矫正视力（BCVA）的最小分辨角对数(logMAR)基线时为 0.85 ± 0.57，首次注射后为 0.86 ± 0.63，每月多次注射后为 0.84 ± 0.64。首次注射后 1 个月时，39.5%的患者视力改善，每月多次注射后 1 个月时，45.2%的患者视力改善。在亚组分析中，首次注射后 1 个月和每月多次注射后 1 个月，后囊下眼的 CFT 分别显著下降至基线值的 85.8%和 79.8%。无后囊眼的 CFT 分别下降至基线值的 91.6%和 87.4%，但无统计学意义。
结论
每月注射玻璃体内抗 VEGF 药物可改善玻璃体切割术后 nAMD 眼的解剖结构，并维持视力。
Zotero 插件